Japanese researchers have succeeded in experimeing that can predict the dangerous side effects of cancer therapy before it happens.
According to RCO News Agency, Medical researchers at the University of Kyushu in Japan have been able to predict the side effects of cancer immunity before occurring by ideifying a specific protein in the spinal cord collected before treatme that could affect the ceral nervous system after treatme.
Japanese researchers say cancer therapy can be safer. The findings of this study allow physicians to ideify high -risk paties and preve these dangerous conditions for paties by prescribing early treatme.
Cancer immune therapy (the use of the patie’s immune system to fight cancer) has become a promising way to combat the disease in the past decades. One type of immune therapy called “Car-T” using genetic engineering to re-program immune cells (T Cells) to target and destroy cancer cells.
This method has been successful in the treatme of leukemia, but has also been associated with a high risk, including “neural toxicity associated with immune cells” (ICANS). This syndrome causes swelling in the ceral nervous system.
Dr. Yuya Kunisaki, a professor of clinical and medical chemistry at the University of Kioshu, said: “ICANS can be associated with mild symptoms such as headaches and numbness, but in more severe cases in paties with consciousness, seizures or bloodshed in the brain.
He added that the occurrence of ICANS after Car-T treatme is highly high. There are about 64 % likely to develop, but so far there has been no reliable way to preve the severity of the disease.
In this experime, the researchers analyzed the proteins in the residual spinal fluid taken from 29 paties with “B-Cell Non-Hodgkin’s Lymphoma). In that group, 11 paties had ICANs and 18 did not.
Researchers ideified 864 proteins prese in spinal fluid samples. They reduced the list of proteins with a sharp difference between paties and those who have not been infected to 46 proteins. This made them poteial biological markers to predict the conditions.
Finally, the researchers were able to discover the C1RL protein in advanced ICANS and Fuca2 protein in the milder stages of ICANS, which had a great role in predicting.
Looking at both proteins, the predictor testing of their proportion in distinguishing paties with high risk of ICANS and low -risk paties with high precision.
The researchers then tested the biomarkers of C1RL and Fuca2 proteins in the second group, along with 10 CAR-T paties. They found that the protein ratio correctly ideifies the risk of ICANS.
However, the researchers warned that despite the high accuracy of the study of these proteins, due to the limited samples of this study, their findings were still in the preliminary phase.
Dr. Tomoko Nomiyama, a clinical technician in the clinical and medical chemistry departme at the University of Kiosho University and authors of the study, said: “We need more paties to test our research.”
The research team hopes that the research, in addition to helping physicians diagnose ICANS earlier and faster treatme, will allow physicians to reduce the risk of ICANs before the CAR-T treatme key and prescribe preveive drugs. For example, the C1RL protein, which rises in paties with ICANS, relates to the suppleme system (part of the immune system that causes swelling and helps ICANS).
“If the biological marker ratio shows the high risk of ICANs, we can begin preveive treatme with the drug that inhibits the suppleme system and reduce the risk of developing,” Konisaki added. These tests can pave the way for a more secure and more personal approach to treating cancer.
The research team also seeks to measure the accuracy of these biomarkers in paties with differe types of leukemia and beyond the “non -cell cell -cell lymphoma”. They also iend to expand their research and hopes to discover the key to biomarkers in collected liquids such as blood serum.
“The process of collecting spinal cord fluid is a painful and aggressive process, so most Japanese hospitals and other couries do not do so before Car-T treatme,” Nomiama said. If we can ideify similar biological markers in the blood, our tests will become a simpler and more accessible tool for ICANS.
This study is published in the journal Leukemia.
The end of the message
(tagstotranslate) Cancer Treatme (T) immune therapy
